So Eisai employee Hampel is publishing "years old data" because he needs street cred? Right....
The paper is about measuring response, not response per se.
Of course cognition is not the only symptom of Alzheimer's so the fact that M1 does not directly affect cognition is only a piece of the puzzle.
Your argument ignores the fact that the P2a was about dose response, efficacy was not promised or expected.... still there was evidence of efficacy.
After reading the publication I see why the company spent millions and delayed trials for another year+ to try to find anything to keep the hope alive. The drug is essentially producing the same results as Aricept and in some cases worse. F1ash has posted multiple times the charts showing what you would expect to happen in these trials of mild patients over time and this publication mimics it to a tee. In fact in that population you would expect a few to improve, many to stay the same for over a year, and the rest to fall off. I truly hope Anavex shows promise for PDD and Rett and even AD, but we are talking a really long road on the AD front. Hopefully PDD is a success this summer. All is JMHO
Market Data 
Markets 
AI
